BioArctic Stock

BioArctic Rule of 40

The Rule of 40 of BioArctic (BIOA B.ST) as of Aug 16, 2026 is 739.77 %. In the previous year, Rule of 40 was -144.54 % — a change of -611.82% (higher).

Rule of 40

739.77 %

YoY

-611.82%

Last updated:

Rule of 40 of BioArctic is 2026 739.77 % . Rule of 40 of BioArctic was 2025 -144.54 % . It decreases by -611.82% higher compared to the previous year.
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Rule of 40 of BioArctic is 739.77 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 BioArctic since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

Quality — BioArctic

All Key Metrics — BioArctic